Nkgen Biotech Inc. ((NKGN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nkgen Biotech Inc. (NKGN) is conducting a clinical study titled A Phase I/IIa Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer’s Disease. The study aims to assess the safety and tolerability of SNK01, a novel immunotherapeutic drug, and its potential to improve cognitive functions in patients with moderate Alzheimer’s Disease.
The intervention being tested is SNK01, an innovative cell-based therapy that utilizes patient-specific, ex vivo expanded autologous natural killer (NK) cells. This biological treatment is administered intravenously every three weeks for up to one year, with the goal of enhancing cognitive assessment scores and biomarkers in participants.
The study employs a randomized, sequential intervention model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose of this interventional study is treatment-focused, aiming to explore the therapeutic benefits of SNK01.
The study began on December 6, 2023, with an estimated primary completion date yet to be announced. The latest update was submitted on June 18, 2025, indicating ongoing recruitment and progress in the trial.
For investors, this study could have significant implications for Nkgen Biotech’s stock performance, especially if SNK01 demonstrates positive results. Success in this trial could position Nkgen as a leader in Alzheimer’s treatment, potentially impacting investor sentiment and market dynamics in the biotech sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.